Multiple Sclerosis

The study presented at CMSC 2017 compared the treatments to an interferon.

Stephen Krieger, MD, an associate professor at Mount Sinai Hospital, discusses the impact that recently-approved drug ocrelizumab has on the state of multiple sclerosis care, as well as his patient-centered app that depicts the MS condition in a more accurate manner, at the 2017 Consortium of Multiple Sclerosis Centers in New Orleans.

Allen Bowling, MD, PhD, physician associate of the Colorado Neurological Institute, discussed widely-researched benefits of cannabis on MS effects, its shortcomings, and the broad outcomes of alternative treatment.

Clyde Markowitz, MD, director of the MS Center at the University of Pennsylvania, discusses how the patterns of male-to-female ratio in MS diagnoses may be linked to hormones, and whether testosterone could be key in bettering treatment.

At CMSC 2017, Aaron Boster, MD, neuroimmunologist for OhioHealth Neurological Clinicians, discussed why he believes there's never been a better time of opportunity for multiple sclerosis patients, and what must be improved in MS diagnosis practice.

Regular access to care could have a major impact on outcomes for neurological patients.

MS patients can exhibit warning signs 5 years before onset.

The 2nd of Celgene's phase III trials with the treatment proved promising.

The training software greatly improved cognition over computer games.

It took 5 visits to the doctor to correctly diagnose many MS patients.

Cannabis gum may be on the horizon for patients with multiple sclerosis.

Smokers found to have altered levels of MAIT than the general population.

Follow-up data from TOPIC, CARE-MS II trials positive for the two MS drugs.

“This appears to be a very safe and effective drug, and is a valuable part of our therapeutic armamentarium. I don’t think teriflunomide addresses all the unmet needs in MS, in fact, no drug meets all the unmet needs, but this is a very well tolerated oral agent.”

The nearly 7-year extension trial presented a 47% reduction overall in conversion to clinically definite MS with those patients who had been on 14mg of teriflunomide from the beginning.

Ocrevus reduced all 3 aspects of relapsing MS disease: reduction relapses, reduction disability, and reduction lesions within the brain quite substantially.

Tecfidera and Tysabri can provide MS patients with positive outcomes.

Researchers previously only considered ALS as one illness, but new knowledge has changed that mentality and has shown experts they need to personalize treatment approaches. “It’s important to understand the disease in different groups of people.”